ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
HALIFAX, NS, May 30, 2023 /PRNewswire/ – ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, has received approval for its Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) to commence a multi-center pivotal clinical study in the United … Read more